Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential and Maintenance Icotinib vs Maintenance Icotinib in NSCLC
NCT02194556Phase 4Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Jul 2014
- Primary completion
- Jul 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Status: unknown.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02194556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02194556.